Header Graphic
Links Page

Fu, C, et al. Clin Cancer Res 7: 4182-4194 Fu, C, et al. Clin Cancer Res 7: 4182-4194


This research paper describes the discovery of HP59, the tumor capillary lectin marker that is the target of the Group B Streptococcal toxin (GBS Toxin), CM101, the etiologic agent for "Early Onset Disease", and the biological that targets tumor neovasculature.

HP59 Wikipedia Page HP59 Wikipedia Page


Wikipedia page describing HP59, fully referenced.

Phase I Clinical Safety Trial for CM101

 

DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan H-P,

Carter CE, Wang Y-F, York GE, Zhang M-H, Johnson DH.: A phase I study of the antineovascularization drug

CM101. J Clin Canc Res, 3, 365-372 (1997).

Review on angiogenesis-vasculogenesis


 




Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma



Mary J. C. Hendrix, Elisabeth A. Seftor, Angela R. Hess & Richard E. B. Seftor



Nature Reviews Cancer 3411-421 (2003)